BillionToOne, Inc. (BLLN) Earnings Call Transcript
March 4, 2026
Earnings Call Speaker Segments
Hello, everyone, and welcome to this afternoon's conference call. Joining me from BillionToOne are Co-Founder and Chief Executive Officer Oguzhan Atay, along with Chief Financial Officer Ross Taylor. The company released its financial results today for both the fourth quarter and the full year concluding on December 31, 2025. That press release is available on BillionToOne's website. Before we begin, please note that statements made during this call may include forward-looking statements as defined under federal securities laws. Comments regarding upcoming developments might address things like our monetary projections and results, the scale of the market, what we offer, reimbursement, how our clinical work will perform going forward, and comparable topics; keep in mind that anything of this nature represents what we presently consider our soundest assessment, and outcomes in reality may diverge substantially from what those forward-looking statements convey or suggest. Factors carrying risk that might lead our results to diverge are covered in the documents we submit to the SEC, among them the registration statement on Form S-1 we filed earlier, the quarterly report on Form 10-Q we filed earlier, the annual report on Form 10-K that will be submitted after this call concludes, and the current report on Form 8-K submitted today. Whatever predictions get shared on this March 4, 2026 call reflect only where things stand right now. Should someone listen again or go through it later on, what was discussed might no longer hold true or be correct. Except where the law demands it, BillionToOne takes on no duty to revise such statements publicly, whether due to fresh details, upcoming occurrences, or anything else. Oguzhan, over to you.
Good afternoon, everybody, and thanks for being here on our call covering the fourth quarter and the full year 2025. BillionToOne has had an excellent year. To start, I'd like to say how genuinely proud I feel about everything the team pulled off during 2025. That was the year we demonstrated what can be accomplished through disciplined, relentless execution. During this year, we didn't merely march our 20 miles. We also went public while a government shutdown had frozen the IPO markets, and we delivered what I consider one of the most extraordinary annual financial results molecular diagnostics has ever seen. Let's turn to our metrics. Set aside the Rule of 40. Looking at how we did for all of 2025, we came in above the Rule of 100. For the entire year, our growth reached 100% compared with the prior year, and we also delivered a 13% adjusted EBITDA margin, a GAAP operating margin that was positive, and positive cash flow. Achieving an organic Rule of 100 is rare among publicly traded companies; in the molecular diagnostics space, my view is that it may have never happened before. That revenue increase was driven by sharp gains in both the number of tests and our ASPs. Compared with full year 2024, test volumes climbed 51%. Our ASP went up 35%. At the same time, we continued bringing costs down and becoming more efficient. On the cost side, the amount we spent per test dropped more than 10%, and that happened during a period when we were expanding our oncology business and processing a much larger volume of oncology tests, which come with higher costs. Because of that, our gross margin improved by 15 percentage points. Then, with AI and automation rolled out across every function, the productivity improvement was even more dramatic — our GAAP operating margin rose by 36 percentage points. That result stemmed from an incredible mix of strong performance from all of our teams. Our sales organization, which is exceptionally strong, exceeded the targets we had set for test volume. Our R&D group continued to innovate, launching several products, including 14-gene single-gene NIPT, which reached the market before our competitors did, and Response V2, featuring a 0.01% limit of detection. On the payer side, our market access and clinical affairs groups got Medicare to cover Northstar Select and closed deals with 44 payers. That brought in more than 25 million additional lives, which pushed our total contracted lives within the US to 250 million. Then there's our prenatal medical affairs team, which drove changes to medical guidelines and the standard of care through UNITY Fetal Antigen NIPT. There's no question that in 2025, each team turned in outstanding work. For us as a public company, this marks just the beginning, and I'm eager about what 2026 and the years ahead will bring. As all of you know, at BillionToOne we see 4 pillars of differentiation that we believe set us apart as an unusual kind of molecular diagnostics business. Everything we do traces back to our revolutionary technology platform. This platform is made possible by our patented QCT, Quantitative Counting Templates technology, which delivers single molecule level sensitivity and precision with next-generation sequencing; using our technology, we've built unique category-defining products in both prenatal and oncology. When it comes to prenatal care, UNITY provides thorough screening off just one blood sample, which is transforming noninvasive prenatal testing as a field. On the oncology side, Northstar Select picks up 50% more actionable variants than other liquid biopsies do, and NorthStar Response offers oncologists an accurate, real-time picture of how effectively a treatment is performing. Thanks to these offerings, we've seen exponential growth, and in the fourth quarter we hit a $384 million annualized revenue run rate. That said, in our view, there's a lot more still to be done before we've truly tapped the full potential here. We believe our technology gives us a distinct advantage that should let us pursue a U.S. market opportunity worth over $100 billion down the road. Turning to pillar number three: BillionToOne has established a strong gross margin position, with margins rising past 70%, despite ASPs that remain below scale—particularly in oncology—and while utilizing just roughly one-third of the lab capacity we have today. And last, the thing I take perhaps the most pride in, is how efficiently we've managed both capital and operations, which enabled us to hit GAAP profitability even as we grew at triple-digit rates—a feat I regard as unmatched in molecular diagnostics. The combination of expanding while also staying profitable shows just how special our tech is, because it brings down COGS, and how distinct the lineup we offer is, which delivers incredibly strong sales efficiency, plus the discipline with which we run things. Our aim over the long haul remains the same: build a business that defines its category and become part of the S&P 500. Thanks to what we did in the fourth quarter, we continued taking meaningful steps toward that aim, and the numbers are nothing short of amazing; in fact, everything we achieved in the fourth quarter exceeded what we had anticipated, including the guidance we provided in December. Let's examine the results one pillar at a time. To start, after the quarter wrapped up, we introduced several products that make our competitive edge even stronger. On the prenatal side, we've just rolled out two things at once: an expanded version of UNITY's Red Blood Cell Fetal Antigen NIPT, plus the first and only Platelet Fetal Antigen NIPT. Over in oncology, Northstar PGx launched for pharmacogenomics, and Northstar Select CH launched for clonal hematopoiesis. We also handed MolDX a coverage dossier for Northstar Response that covers 5 studies and 3 peer-reviewed publications. That's a thrilling move toward securing MolDX coverage for the Northstar Response test. Thanks to these differentiated offerings, rapid growth keeps impressing us, with Q4 revenue up 113% year over year. That outstanding expansion, which actually sped up versus the first half of the year, came from test volume climbing 47% year over year alongside a 47% year-over-year rise in ASP. Moving to the third pillar: because average selling prices went up while cost of goods sold for each test went down, our gross margins grew by over 14 percentage points compared with a year earlier, reaching 71.4% during the fourth quarter. And finally, we kept profitability solid in that quarter, posting an 11% GAAP operating margin along with a 19% adjusted EBITDA margin. We closed out the year with a healthy balance sheet, holding $496 million in cash and term debt of roughly $50 million. Ross and I will go deeper into the quarterly financial results. But first, I want to update everyone on our transformative technology platform and our unique products. To begin with pillar one, it's a thrill to share that the Fetal Antigen NIPT offering we have on the market today is already transforming how care is delivered. Let me remind everyone that no other test like our Fetal Antigen NIPT exists anywhere in the United States. When blood incompatibility between mother and fetus is a possibility, it establishes whether the fetus tests positive or negative for a range of red blood cell antigens, Kell among them. This situation arises when a pregnant mother generates antibodies targeting a red blood cell antigen that could either be present or absent in the fetus. This matters enormously for the patients involved and for the maternal-fetal medicine specialists who care for them — it's a very serious situation. Pregnancies with this kind of alloimmunization show up more frequently than aneuploidies do. Absent our tests, MFMs typically have to monitor and test these high-risk pregnancies every week. Our UNITY Fetal Antigen NIPT figures out whether the fetus lacks the antigen the mother is producing antibodies against, and that eliminates the costly, time-consuming monitoring that fetal antigen negative pregnancies would otherwise require, while also removing the uncertainty these patients live with.
And notably, in November, a committee of experts made up of MFM key opinion leaders put out a clinical practice guideline, and in my view its recommendations are more robust than anything released in cell-free DNA for any test in any context. The committee stated — and here I'm quoting — that we recommend using cell-free fetal DNA to accurately establish fetal red blood cell antigen status from blood drawn beyond 10 weeks gestational age in pregnancies complicated by alloimmunization. They also underscored how dependable our results are, recommending that once our NIPT shows the fetus is negative, no additional surveillance is required for the rest of the pregnancy. With that backdrop, I'm thrilled to share that we recently broadened our Fetal Antigen NIPT and introduced our first-and-only Platelet Fetal Antigen NIPT at the Society for Maternal-Fetal Medicine Conference in February. As I noted, for MFMs this ranks among the most significant issues in prenatal care, and response to the product launch was overwhelmingly favorable; over 100 physicians came to our dinner presentations at 3 venues during the conference — an absolute record for us across any conference we've ever taken part in — plus a conference presentation that was standing-room only with over 100 more attendees; through this dual launch, first, we broadened the antigens we detect for red blood cells, which now cover 99% of antigens tied to Hemolytic Disease of the Fetus and Newborn, or HDFN. We also introduced the first-and-only NIPT for platelet incompatibility, addressing FNAIT. FNAIT is a serious condition that can cause catastrophic fetal outcomes, such as intracranial hemorrhage or fetal loss. These fetal antigen tests are offered exclusively through our UNITY Aneuploidy Screen, requiring no extra order or blood draw. This powerfully showcases the depth of our smNGS platform. As I noted, these high-risk pregnancies occur more often than aneuploidies, and we're eager about the clinical impact these expansions will deliver; we think these tests hold enormous potential to help patients who would otherwise require weekly monitoring, testing, intervention and management by MFMs. On the oncology side, following the quarter's end, we released 2 significant upgrades to Northstar Select, 2 add-on tests for pharmacogenomics and clonal hematopoiesis. Rolling out these applications for Northstar Select broadens our product to tackle 2 critical decision points in therapy selection. They also keep us in step with evolving oncology treatment guidelines — information that matters more and more to how oncologists choose therapies. The PGx add-on delivers pharmacogenomic insight into key variants for chemotherapy dosing. From the same blood sample and within the same 5-day average turnaround time, Northstar PGx can report a patient's predicted metabolizer status and associated clinical implications. That lets the physician use the right dose for each patient, preventing severe toxicity, reducing hospitalizations and improving safety and quality of life. Northstar Select CH addresses clonal hematopoiesis, the most common source of biological false positives in cell-free DNA testing. A striking 25% of patients carry at least 1 CH mutation in a gene that is actionable. Those CH mutations come from white blood cells rather than from the tumor. Put differently, they represent biological false positives, and they may result in patients receiving therapies that do not work. Northstar Select CH pairs targeted white blood cell sequencing across every guideline-recommended gene with proprietary machine learning classification covering all remaining genes, delivering better than 99% accuracy when telling tumor-derived alterations apart from non-tumor findings. In our view, Northstar Select CH stands apart strongly from competing offerings because it provides liquid biopsy results that are more accurate and more trusted. Although we demonstrated earlier that Northstar Select is meaningfully more sensitive than rival liquid biopsy products, we think this offering will additionally establish it as the liquid biopsy with the greatest specificity. As physicians become more aware of the CH problem, we anticipate that white blood cell testing will serve as a key factor driving which liquid biopsy they choose. PGx and CH are both ordered as add-ons when Northstar Select testing occurs, and both are integrated within a single report; through these upgrades we stay at the leading edge of therapy selection. Now to our second pillar. Our product innovation leadership and our expanding commercial team keep fueling our test volume, with Q4 hitting roughly 170,000 tests, up 47% year-over-year. We achieved robust quarter-over-quarter growth in both prenatal and oncology even though Q4 is a seasonally slower period with fewer accessioning days. Notably, during Q4 we brought on a record number of new active ordering providers, which we believe positions us for a strong Q1 2026; we monitor this metric closely and the momentum encourages us. Our sales team keeps delivering extremely high sales efficiency, and we keep growing our commercial team at a systematic pace. Our total revenue results in the fourth quarter illustrate the exponential growth achieved since 2021, climbing from approximately 0 to $384 million in ARR over roughly 5 years. Fourth-quarter total revenue came to $96.1 million, which represents 113% year-over-year growth, propelled by swift gains in tests delivered and ASPs across both product lines. Sustaining this level of growth at our scale is genuinely differentiated within our industry. This outperformance stemmed from rapid expansion in prenatal and oncology revenues alike. Prenatal revenue during the fourth quarter totaled $86.9 million, a 98% year-over-year rise, hitting an annualized run rate of $348 million. Our prenatal revenue keeps expanding at a rate that highlights how deeply differentiated UNITY is. Our oncology revenue kept growing even more quickly than prenatal, arriving at $9.1 million in the fourth quarter and reaching a $36 million annualized revenue run rate. That marks a 736% year-over-year increase. The oncology ramp has come from rising adoption of both Select and Response, execution by our oncology commercial team, and the advantage of MolDX coverage for Select secured earlier in the year. Specifically, if you leave out true-up revenue, our oncology revenue was up 29% from one quarter to the next, mostly because our test volume increased. Since PGx and CHIP joined in Q1, we anticipate that our test volume growth for 2026 will be even more robust. We keep seeing a major opportunity ahead as we expand our sales team, develop clinical evidence and seek Medicare coverage for Northstar Response. Beyond the growth in our test volume, our overall ASP is also still climbing quickly. Overall ASP rose by another 12% quarter-over-quarter, going from $501 to $561 — that's a notable $60 per test gain in just one quarter. Across all of 2025, our overall ASP went up from $368 in 2024 to $495 in 2025, which is a 35% year-over-year ASP increase. The Q4 sequential step-up of $60 per test matters and shows a number of converging tailwinds. More Medicaid states are adopting our Carrier PLA code, our contracted payer base keeps building out, and oncology is contributing more, since Northstar Select carries a far higher ASP than any of our other tests; we think there's still considerable room for ASP expansion as we bring on additional payer contracts and as guidelines keep widening the clinical indications for our tests. We're especially enthusiastic about the possibility of Northstar Response coverage.
Because Northstar Response is a repeat-order product, it makes up nearly two-thirds of the oncology tests we run, so even a small lift in its coverage and ASPs would drive a substantial gain in our oncology revenue. Beyond pushing ASPs upward, we've stayed true to our operating approach of never-ending enhancement aimed at bringing down COGS per test. During Q4, our total COGS per test came to $161, a 4% decline versus the same period a year earlier. Worth pointing out: COGS per test edged up a bit from the prior quarter, largely because of a sizable and ongoing move toward a greater share of oncology tests, which carry both higher COGS and higher ASP per test. Another factor was greater stock-based compensation expense tied to being a public company. To keep our downward path on COGS per test going, we keep putting AI and automation to work throughout our lab operations. With ASPs rising and COGS per test falling versus a year ago, our gross margin picture kept improving during the fourth quarter. Q4 gross margins reached 71.4%, which is a 14.3 percentage point gain over the prior-year period and a slight sequential improvement from 70% in Q3. The main drivers behind the gross margin gain were stronger overall ASPs and ongoing headway on lowering COGS per test, particularly within oncology. Something especially worth highlighting: gross margins keep climbing even as oncology, which today carries lower margins than prenatal, contributes a bigger share of volume. We're pleased with how margins are trending in both segments. And although the ongoing mix shift toward oncology will cap meaningful margin gains in the near term, we anticipate holding gross margins around where they are now. Finally, on our fourth pillar, we reached GAAP profitability for both Q4 2025 and the full year 2025, delivering year-over-year gains of 29 percentage points in net margin and 36 percentage points in operating margin. Several things got us here: rising and elevated sales efficiency, higher ASPs, lower COGS per test, and our unyielding commitment to boosting productivity everywhere in our operations via automation and AI. I want to point out that we've reached this profitability at a far smaller scale than our rivals, all while expanding more quickly and carrying under 10% of the accumulated deficits they have. With that, I'll hand the call to Ross, who will walk through our financial results and 2026 guidance before I wrap up.
Appreciate that, Oguzhan. To build on what Oguzhan mentioned, our total revenue for Q4 of 2025 came to $96.1 million, compared with $45.1 million during the same quarter in 2024 — a rise of 113%. During the quarter, both the prenatal and oncology product lines delivered strong growth. Prenatal revenues — consisting of $86.1 million from clinical testing along with $800,000 from clinical trial support and other services — grew 98%, hitting $86.9 million in Q4. As for oncology, revenues for Q4 of 2025 reached $9.1 million, an increase of 736% versus the fourth quarter of last year. During Q4, the two product lines together generated $8.4 million in true-up revenue. That compares with $1.1 million in the same quarter a year earlier, and it signals improving cash collection patterns related to tests that had been delivered in prior periods. For the quarter, our revenues finished above the guidance range we issued on December 9, which had been $84 million to $90 million for Q4. Of the amount by which Q4 revenues beat the top end of that range, about 2/3 was driven by test volumes coming in above what we had projected, and 1/3 came from true-up revenue doing better than we had estimated. For the fourth quarter of 2025, gross profit came in at $68.6 million. That compares with $25.7 million for Q4 of 2024. Our gross margin in the fourth quarter of 2025 was 71.4%, versus 57% in the fourth quarter of 2024. A key point: across all of our product lines, both ASPs and cost-per-test improved on a year-over-year basis. Operating expenses for Q4 of 2025 totaled $58.3 million, compared with $37.4 million in the same quarter a year earlier — that's a 56% increase. Turning to the expense side, R&D came in at $14.3 million for Q4 2025, up from $11 million during the same quarter a year earlier. SG&A, meanwhile, reached $44 million in the fourth quarter of 2025 versus $26.4 million in the prior-year period. We continue to grow our cost base in a way that fuels fast expansion while staying efficient and disciplined. On profitability, we posted operating income of $10.3 million in Q4 2025, a swing from the operating loss of $11.7 million recorded in the fourth quarter of 2024. Our operating margin for Q4 landed at 11%. Looking ahead, we plan to manage the company so that GAAP operating income remains positive. For the fourth quarter of 2025, net income attributable to common shareholders came to $4.4 million, equal to $0.11 per diluted share. During the same quarter in 2024, we posted a net loss of $11.5 million, which worked out to $1.13 per diluted share. Now let me quickly walk through some 2025 financial highlights. We brought in total revenue of $305.1 million, which topped our guidance range and represented a 100% increase over the $152.6 million reported for 2024. Full-year 2025 true-up revenue reached $17.1 million, up from $11.2 million in 2024. Tests delivered during 2025 rose 51% to 610,000, while our overall ASP climbed 35% to $495. Operating income for 2025 stood at $16.0 million, a swing from the operating loss of $47.1 million we had in 2024. For the whole of 2025, our operating profit margin landed at 5%. Adjusted EBITDA reached $38.8 million, translating into a 13% margin. We achieved that despite spending heavily on expanding our sales force, launching new products, and building out clinical evidence. Our cash flow continues to be strong. Operations-generated cash less capex came to $9 million in Q4 of 2025, and across the full year 2025 it hit $16 million. As you build your models, we'd anticipate diluted shares outstanding settling in the range of 52 million to 54 million over the quarters ahead. Our capital position is strong, and the balance sheet is very healthy. We closed out the year holding roughly $496 million in cash and equivalents alongside only $50 million in term debt, which sets us up well for robust expansion ahead. Last, an update on the full year 2026 guidance: we're lifting our 2026 total revenue outlook to somewhere in the range of $430 million to $445 million, which means growth between 41% and 46% versus full year 2025. On top of that, we still anticipate positive GAAP operating income for the whole of 2026. This new revenue guidance adds $15 million at each end of the range compared with what we gave you back in early January, which was $415 million to $430 million. At this point I'll hand the call back to Oguzhan, who will go deeper on the guidance and wrap things up.
Thanks, Ross. I want to point out that we have a number of other growth drivers and catalysts across both prenatal and oncology, which give us a lot of confidence that even the guidance we've raised is on the conservative side. On the prenatal front, the momentum we're seeing continues to be very strong; we think the clinical practice guideline that came out recently will push UNITY even further toward becoming the new standard in prenatal care, and will reinforce BillionToOne's position as the leading innovator in this space. At SMFM, we're doing a dual launch — our expanded Red Blood Cell Fetal Antigen NIPT and the first-and-only Platelet Fetal Antigen NIPT — and that will drive additional growth for us. As awareness builds and adoption is driven by practice guidelines, we anticipate a meaningful uplift in volume within health systems where MFMs hold decision-making authority. That kind of health system adoption isn't baked into our guidance. We're also seeing ongoing ASP tailwinds from growing Medicaid coverage of the PLA code for our Carrier panel. Ten Medicaids have added 0449U during 2025, with the biggest of those coming in Q4, and Florida will begin covering 0449U in Q1 2026. Every Medicaid addition has the potential to lift ASP and open the door to more contracting with managed care organizations, or MCOs, which in turn drives our test volume in a flywheel effect. There are also multiple health systems that want to make UNITY their prenatal screening of choice, and the only thing still standing in the way is EMR integration. Epic Aura integrations probably won't begin until 6 months from now, so their contribution isn't reflected in our guidance, but adoption by even one health system could be a significant upside to our projections. On the oncology side, launching Northstar Select PGx and Northstar Select CH widened our oncology portfolio and strengthened the value proposition we offer oncologists. As our test volumes increase, we can push our COGS per test lower and enable further product innovation, including a best-in-class tumor-naive MRD that we're aiming to launch by the end of the year. Each one of these is a standalone growth driver that compounds with the rest. Lastly, our MolDX coverage submission for Northstar Response is a meaningful catalyst. We've submitted a comprehensive coverage dossier to MolDX, and an approval arriving even a few months ahead of year-end would represent meaningful upside to our 2026 oncology revenue, since Northstar Response makes up nearly 2/3 of our oncology test volume. And there's one more catalyst I want to focus on for a moment, specifically because I think it could be quite significant for us in 2026. Beyond all the drivers I just mentioned, I'm extremely excited to share that we have just signed a contract to be in-network with UnitedHealthcare, the largest commercial health insurer in the United States. This is a landmark moment for BillionToOne, and I want to take a moment to explain why. When we're out of network, patients can still get access to our tests, but it can create significant friction for both physicians and patients. It also leads to reduced ASPs, since what patients pay can be inconsistent and hard to manage. Signing an in-network agreement wipes out that entire set of headaches in one move. My expectation is that our work on contracts with additional payers will pick up even more speed during 2026, which should push up both the number of tests we run and our ASPs. The market access group here has laid a truly strong groundwork. They make me extremely proud; to put it briefly, we are reshaping health care, one molecule at a time, one patient at a time. We proved that what this industry assumed could not be done in cell-free DNA diagnostics was in fact achievable, and our journey has only just begun. To keep winning going forward, we need to sustain outstanding execution, and I have full confidence that the people on our team, along with our technology and our products, put us in position to achieve exactly that. During Q4, we kept up that outstanding execution in our 20-mile march. Between submitting Northstar Response to MolDX, bringing out several new products, and achieving a record that had never been reached before for providers placing orders for the first time, the team is pushing ahead on all pillars of the business at the same time. In fact, during Q4 we grew gross margin and stayed GAAP profitable even while taking on onetime costs tied to our IPO and ramping up our investing pace. What makes me feel the greatest confidence when I think about what lies ahead isn't some individual catalyst; it's how everything we've constructed compounds over time. Every product we bring to market makes our smNGS platform stronger. Each study we release expands our clinical evidence base. Each new active provider we bring aboard makes our commercial organization more productive, and each payer contract we finalize — such as the landmark deal we have just announced — improves our market access standing. Ours is a group of motivated, purpose-built people who show up each day to make patients' lives better. That dedication is the force behind everything reflected in these results. Our ambition over the long term is to create a category-defining company, join the S&P 500 and keep reshaping health care, one molecule at a time, one patient at a time. Each quarter, we feel excited to move one more step toward that goal. And my belief is that 2026 will prove our most consequential year so far. Thank you. I'll hand things to the operator.
I appreciate the comments. There's definitely plenty here to unpack. Oguzhan, you brought up how the prenatal portfolio keeps growing as you keep advancing that area; and obviously, my sense is this kind of raises how aware certain providers are of UNITY. But zooming out, could you perhaps just describe where you believe awareness stands among all providers ordering NIPT, including those handling low-risk and high-risk pregnancies. And then in what way — how do you think about pushing that up during 2026 and afterward?
Thanks, Andrew. That's a really good question. And in fact, this is among the reasons we think our ongoing growth has such a lengthy runway. When we — I believe this shows up in a few of the surveys that analysts and others, yourself included, have assembled. But what our own data shows us is that roughly — whether you're looking at aided or unaided recall, no less than 50% of providers are completely unfamiliar with UNITY. So that's actually a striking result: among providers who are familiar with UNITY, we hold more than 50% market share, or thereabouts. Roughly — unaided awareness sits at about 30%, I believe, while aided awareness sits at about 50%. So when you consider those figures and we examine basically what share of them are in fact using UNITY, we have roughly 50% market share when a provider is familiar with our tests. So seen that way, we're confident that as our sales team keeps getting bigger, as we keep achieving full coverage across the entire United States, and as we keep publishing plus see these clinical guideline updates and other added products with UNITY, we're confident this awareness will rise, and that will serve as a truly significant engine for our growth over the long term.
Then, as a quick follow-up, perhaps you could expand on what you said regarding health systems, since MFMs play a key role as decision-makers in that setting. Could you describe the kinds of discussions you are currently having with those organizations, especially when it comes to encouraging adoption among these bigger groups?
Absolutely. MFMs matter a great deal as a stakeholder group, correct? Typically, they are the physicians managing pregnancies that carry high risk; and whenever an NIPT comes back showing a high-risk finding, those patients generally get sent to MFMs; so viewed from that angle, MFMs wield enormous sway regarding which tests are chosen by the OBs who send their high-risk patients over to them; so broadly speaking, this matters within health systems where those OBs and MFMs collaborate very tightly, yet it actually matters just as much beyond the health system setting, where an MFM can approach the OBs who refer patients to them and state that, I would prefer — assuming they strongly champion UNITY, they are able to say that, I would prefer that you adopt UNITY for your frontline screening, so that when these high-risk patients reach me, I possess every piece of information required to counsel them, to manage them, and to treat them.
Oguzhan, could you perhaps discuss that higher provider figure you brought up regarding Northstar? As a metric, how are we supposed to interpret it? When it comes to onboarding new doctors this year, what would count as a solid outcome versus a weak one? It would just be useful to grasp how you're growing adoption in the market.
Thanks, Dan. What I was pointing to combined both prenatal and oncology. So, examining how many ordering providers — those actively ordering — we had each quarter, what we observed in Q4 is that the count of active ordering providers rose quite substantially. Regarding active ordering providers we managed to bring in, that quarter was our best. Typically, this signals quite robust growth ahead for Q1. As we've said before, since Q4 contains fewer accessioning days, the actual effect on growth in test volume generally doesn't show up in the Q4 figures. Yet, if you consider the count of active ordering providers — and our threshold for labeling a provider as actively ordering is genuinely high. Should someone order merely 1 or 2 tests, that isn't counted. So in that light, what that remark truly points to is this: relative to every earlier quarter, Q4 was in fact the strongest one for gaining new active providers who aren't simply dabbling or ordering 1 or 2 tests, but who use our products on a regular basis during the quarter, which typically serves as a very strong indicator of where Q1 test numbers will land.
All right. All right. Then, Ross, Oguzhan said something regarding gross margins. Should we take it that the presumption is that gross margins remain flat across the year? And after that, do you feel at ease with that throughout the guidance range and throughout the variety of mixes that could come up? I realize you have the ability to manage that mix, but I simply want to be sure that this is a number you can fully stand behind in any scenario.
Yes. That's a fair question, Dan. I believe we aren't providing much detail on gross margins or certain expense lines, aside from stating that we intend to run the company with positive operating income on a GAAP basis moving forward. Still, my expectation would be for gross margins to remain elevated in that high 60-ish area. Perhaps we might keep going somewhere within this 71%, low 70% area. However, I believe I wouldn't be aggressive whatsoever when it comes to expectations for gross margin expansion.
Congratulations on a great year, and there's clearly plenty to unpack here too. I'd like to ask about the United contract becoming in-network. My assumption is that this applies to UNITY, even though UNITY isn't the sole product you have on the market. So could you just clarify which products fall under the United contract? And then, looking back at diagnostics, there are times when companies work out in-network deals with big health plans, and they may need to accept a price discount. Could you just address how we ought to think about that dynamic, and whether we should anticipate somewhat lower ASPs because of this move to in-network?
Thanks, Mark. My view is that you should anticipate higher ASPs from here on. Over the last 4 years, we've signed what is likely near 200 contracts, and none of them brought our ASPs down. So in that light, once you become in-network with a payer on a broader basis, the result is that you do accept a percentage of Medicare within that contract. Yet that also means you receive dependable reimbursement for that percentage instead of the sum that actually goes toward patients' coinsurance and deductible. So since patient collections are not — are never truly 100% no matter how hard you try, what usually occurs is that you may accept a lower percentage, say, 80%, 70% of Medicare, yet that winds up being substantially greater than what you'd get otherwise on a blended ASP basis. I'm unable to discuss contract specifics because of confidentiality reasons. But what I'd add is that we, again, also generally find that with each contract we sign, it actually covers both — all the products you have. It covers prenatal and oncology products; that doesn't mean that a test — every test will be paid, correct? It is — you must have the coding, and you must have the coverage too. So you must have the contract, and the contract will cover whatever codes you have, but beyond that there also needs to be — coverage has to exist for a test to be paid. So in that light, a benefit does arise. And again, this is public information available through UnitedHealthcare, including through many of the commercial contracts we hold.
All right, that's helpful. And for a follow-up, could you describe what you're observing out in the field? I'm aware that Natera introduced Fetal Focus — are you detecting any effect from that? Then, if I may squeeze in one more, pharmacogenomics and Northstar Select CH are add-on offerings. Might these be a possible avenue for extra ASP? Put differently, are you going to bill for those tests?
Let me start with the oncology side of that. Northstar Select CH along with PGx serve as add-ons to the tests we already have. Generally, we don't anticipate meaningful ASP increases arising from add-ons like these, particularly over the near term. Over the longer run, as guidelines shift and existing guidelines regarding ESMO, for example, continue to — they already back buffy coat sequencing when it comes to CH, ASP gains may emerge once these turn into covered benefits; regarding competitors, given that we brought on a record count of ordering providers during Q4, the growth figures for our test volume in Q4, and the pattern of rising prenatal revenues, I believe it's fairly easy to infer that thus far we truly aren't experiencing any effect from competitive pressure.
Oguzhan, you're now in your second quarter of reporting since becoming a public company. Looking back at these first 2 quarters, what's gone the way you expected? What's come in above what you anticipated? And what might have gone better, something you're focused on improving in 2026?
Thank you, Subbu. I'd say we've been running at a similar cadence for 3 years now. Our pre-IPO investors could easily confirm that. We've put out quarterly results and beat and raised guidance for 3 years. Actually, our Board members would tell you we never really missed guidance during the period they've been an investor. So from that angle, everything has followed the plan. That isn't to say that everything you work on essentially winds up — winds up delivering better results; it's just that we work on a number of drivers, and a lot of those drivers aren't baked into guidance. So if certain ones prove out, that still creates upside relative to what we initially thought our results would be. As for what maybe didn't follow the plan, because of perhaps the timing of the IPO and the earnings calls, there have been a lot of conferences and investor meetings and earnings calls; we definitely would rather focus on running the company and building the business than taking part in conferences, no offense meant.
Oguzhan, turning to a fully separate follow-up, you touched on some of the potential upside for prenatal volumes relative to the guidance; but might you walk through what the guidance bakes in regarding prenatal volume growth at present and gains in prenatal market share? And in light of the volume growth you've observed in prenatal, seasonality hasn't hit you; yet as you look toward 2026, do you anticipate more seasonality simply due to the volume, the sheer quantity of volumes?
For us, Q4 is always a slower quarter, generally speaking. As we said before, we — many physicians are unwilling to change their test during Q4. They tend to push that decision off to the start of the year. On top of that, Q4 has fewer accessioning days. Those 2 factors together usually cause our Q4s to be slower. So the fact that we saw no slowdown in Q4 was actually a sign of unusual strength in our business. And I believe that really points very favorably toward what we anticipate for Q1 and for the remainder of the year; regarding what's baked into our guidance, it essentially bakes in the sales team members we currently have and how we anticipate they'll grow quarter over quarter, essentially what's required of them to hold onto and expand each territory. It leaves out much of the upside that could arrive from these big health system opportunities, which could be spurred by either the guideline changes and the new product additions we've made, along with the Epic Aura integrations we referenced. So adoptions by any health system, or anything tied to a health system, aren't truly baked into our guidance.
Nice work on those first two strong quarters since going public. Perhaps I overlooked it, since it's hard to believe nobody brought this up; yet across the past 2 months, at the endpoint you lifted guidance by $15 million. Could you share a few specifics about what actually went well during those 2 months, and what looks different to you? I realize United might be playing a part there. Is United the sole factor? Any other things worth considering?
Any possible upside stemming from United was left out of our revenue figures. The United contract takes effect April 1. In his prepared remarks, Ross had one sentence, I believe, noting that relative to the guidance we gave in December, strength in test volumes produced 2/3 of the increase while higher-than-expected true-up revenue produced 1/3. Basically, we entered December thinking Q4 is usually a bit seasonally slower for us. We had October and November figures, and December turned out to be exceptionally strong on test volumes, and that drove 2/3 of the beat, while 1/3 resulted from the quarter's true-up revenue coming in above what we expected; regarding guidance for the new year, none of the developments, upsides, and drivers we discussed were actually built in. What we did was take the expectation around per test, per sales rep growth across different territories. Then we simply folded in our Q4 quantitative numbers, and this quantitative output is what that model produces. That, in our view, is the reason it's quite conservative.
Great. And then perhaps what I wanted to inquire about is regarding reimbursement tied to response. I mean, what's the status of discussions with CMS? And there aren't many response assays available. I mean, essentially there's Guardant Response. What's your expectation for how this coverage policy might shape up? I realize there are various histology types when it comes to monitoring, perhaps it resembles MRD more. What sorts of factors might CMS weigh, the pushes and pulls? And I'll follow up offline after this.
So under its current policy, MolDX already provides coverage for the idea of treatment monitoring. That policy was primarily drafted with MRD in mind, yet a section exists that in fact addresses their perspective on treatment monitoring, and that gives a clear line of sight into what we must supply. We've begun some of those discussions, but naturally, it always requires a few rounds of back-and-forth submissions before reaching a coverage decision; therefore, that's why we continue to plan for the coverage decision from MolDX for Medicare lives at the end of the year.
I'm just wondering what you're observing in the markets for therapy selection and response monitoring that are competitive, and whether you're running into other rivals in those spaces — one of your bigger competitors has been discussing response monitoring more often. Then I'd also like to know what's baked into the guidance regarding oncology volume growth and how that breaks down between current providers and share gains? And I'd be interested as well in hearing the typical monthly test order volume for existing Northstar Select customers.
Could you say that first question again? That seemed like 3 questions to me. I want to be sure I address all of them.
Yeah. No, I'll take it. Regarding the competitive landscape for therapy selection, you're running into rivals in that space, and in therapy response monitoring too, especially since one of your bigger competitors is discussing that test more often.
Absolutely. And I believe it's a clear acknowledgment that response monitoring is hugely needed. And in the market, we're encountering competition in both therapy selection and response monitoring. When it comes to therapy selection, our ability to identify actionable variants with the highest sensitivity — 50-plus percent more of them — is truly transformative. So for us, the real challenge is getting in front of oncologists, which tends to be the bottleneck. When we're sitting down with an oncologist, we can point to peer-reviewed papers documenting a prospective, head-to-head comparison. Yet suppose that oncologist doubts those findings would hold for the patients they treat. In that case, a figure like 50% more actionable variants is simply too big to dismiss — they really ought to witness it firsthand across 5 or 10 of their own patients. That gives us an opening to propose: how about we run a research trial together, where you enroll 5 or 10 of your patients for research purposes, and you're testing them using standard of care against one of the bigger competitors we have. So in those side-by-side comparisons, we're coming out on top, and honestly, all it takes is a single patient. Say one person's course of care shifts because you caught a variant that could actually be acted on — something that altered how that patient was treated — or because a rival either missed it or misread a CHIP mutation that we correctly flagged as CHIP, letting us say this individual won't benefit from that particular drug. Either way, one patient alone can totally reshape how a doctor thinks about your assay. Just one, and that physician moves beyond being merely a user of your test — they turn into someone who champions it. That's genuinely where we're seeing a flywheel effect. If we start by placing one sales representative in a given territory, the level of competition means it may be 3, 6, or even 9 months before that person manages to sit down with oncologists. The rivalry isn't limited to diagnostics companies. Oncology has a whole array of pharma reps reserving lunch slots, and those lunches eat into oncologists' schedules. Yet once you've got 1, 2, or 3 doctors who have moved beyond simply using the test and become champions of it — who feel strongly about the difference it makes for their patients — they'll send referrals and make the case for your test to fellow physicians, and that gets you face-to-face with those physicians far more quickly. What we're noticing is that across different regions, as we ramp up the number of tests we run, it's getting simpler and simpler, honestly, since we can now get past that constraint of needing to be physically present with oncologists — and that constraint is truly the sole thing standing in the way of our capacity to beat our rivals.
Understood. That helps. And then, sure, perhaps one brief additional question. Regarding oncology volume growth, what is baked into the guidance? Also, how is that divided between expansion from current providers and gains in share? And I'd also be interested to hear whether there's an average monthly test order for existing customers using Northstar Select. That's something we get asked about from time to time.
For the typical number of Select tests per physician, I don't have a figure. As for share gains, or the way we approach the guidance, it's precisely how we consider prenatal; we understand that on average, every one of our sales reps can grow x tests each quarter; and that permits — and we've observed this across the last 2 years with over 40, 45 reps; so basically we build that growth into our oncology test volume increase for 2026.
Ross, when it comes to the guidance, ought we to view the ASP as expanding off that $560 baseline from Q4? And within the revenue guide, are you factoring in any tailwind from true-up revenue?
That's a fair question, Brandon. No true-up revenue is baked into the revenue guide, so it sits outside of true-up revenue. And when you consider our overall ASP, keep in mind that our historical method of calculating it does take true-up revenue into account. So you might want to adjust for that or build in some assumptions there.
All right. So, Oguzhan, could you discuss what's planned for expanding the sales force in '26? You've been adding reps at a fairly steady rate — roughly 8, 9, 10 each quarter in oncology, and the same on the prenatal side. Should we expect that pace to pick up, or will you tweak things because of competition or the new products you're clearly enthusiastic about?
Thanks, Brandon. Like we said in the earnings deck, we anticipate keeping up our expansion in both prenatal and oncology. For prenatal, the plan is to go from about 150 reps to 185 by year-end, while oncology should increase from roughly 45 reps to 65 reps by year-end. We picked this pace not because growing quicker isn't possible — it definitely is. Rather, it's the fastest expansion we're at ease with when it comes to preserving our test quality, correct? You might have the greatest oncology test out there. Yet if your test volume climbs by over 100% year-over-year, keeping the same turnaround time and the same service quality for those tests gets really hard. So basically we're pursuing this highly methodical expansion, also since it gives us a growth rate that we think will let us sustain the same service standard, right? And regardless of how excellent your test is, should your turnaround time shift from 5 days to 15 days, customers will leave, particularly for these extremely time-sensitive, important tests. So viewed that way, how we've structured our sales team growth numbers will let us deliver superb end-to-end service, spanning everything from client services to lab operations and all that we do. And on top of that, it's arranged so that prenatal growth offsets part of the oncology growth when it comes to GAAP profitability.
This is Noah, sitting in for Tycho. To kick things off, I'd like to ask about the opportunity with health systems — specifically, could you give us some context on how you're thinking about its size, and then what the timeline might look like before it potentially starts appearing in the numbers?
Thanks. When we look at the health system opportunity, the way we frame it is that any single health system could represent somewhere in the range of 10,000 to 30,000 tests annually. So these are very large health systems, and they take time — getting multiple stakeholders aligned takes time. We do have several health systems where clinical buy-in exists, but integration with EMR is still required before they're able to roll out our test as their preferred frontline screening option. That piece isn't entirely within our control, correct? What has to happen first is integration with Epic, and after that comes integration with each individual health system, which can take a while. None of these uplifts have been factored into our test numbers for 2026. That being said, based on what we're seeing, particularly in the back half of the year, there may be chances for 1, 2, 3 of these health systems to begin coming in. Naturally, for 2026, you won't witness the complete effect of 10,000 to 30,000 tests if they arrive midway through the year; however, when we look ahead to 2027, those adoptions and those wins will position us for yet another exceptionally strong year of growth.
That gives me some useful context. Now, turning to my second question, I'd like to dig deeper into the guidance. When it comes to 1Q, is there a chance weather could cause some interruptions? And regarding OpEx, should we think about any timing shifts over the course of the year, whether that's related to spending on MRD trials or bringing on extra staff before the launch?
As far as weather goes, there's nothing to anticipate, since our Q1 — with Q4 teeing up Q1 quite well, we're looking at a robust 2026, Q1 included; on the OpEx question, we keep investing at a rate that would keep us GAAP profitable. So no front-loading or end-loading of OpEx is expected from us; the plan is well balanced, not only for this year, but over the next 3 years as well.
Appreciate it, operator, and thanks to everyone for being on today's call; we can't wait to talk with you again on our next conference call a few months from now. 2025 was truly a strong year for us, yet what we'll accomplish in 2026 is something we're anticipating even more. Take care.
This concludes today's conference call. Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete BillionToOne, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to BillionToOne, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.